Asterias Biotherapeutics Inc. Series A
AST
AST was delisted on the 7th of March, 2019.
75 hedge funds and large institutions have $25.5M invested in Asterias Biotherapeutics Inc. Series A in 2017 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 25 increasing their positions, 8 reducing their positions, and 6 closing their positions.
217% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 6
213% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 8
21% more funds holding
Funds holding: 62 → 75 (+13)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
20% less capital invested
Capital invested by funds: $31.8M → $25.5M (-$6.31M)
83% less call options, than puts
Call options by funds: $64K | Put options by funds: $384K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadwood Capital
New York
|
+$4.03M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$232K |
| 3 |
Millennium Management
New York
|
+$149K |
| 4 |
VF
Virtu Financial
New York
|
+$144K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$87.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Family Management
New York
|
-$119K |
| 2 |
CL
CSS LLC
Chicago,
Illinois
|
-$89K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$60K |
| 4 |
NFA
Nationwide Fund Advisors
Columbus,
Ohio
|
-$47K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$42.6K |
AST Hedge Fund Activity: Q4 2017 in Review
75 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Asterias Biotherapeutics Inc. Series A (AST) for Q4 2017, worth a combined $25.5M — down 20% from $31.8M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new AST positions and 6 closed out — a net gain of 13 holders — while 25 added to existing stakes and 8 trimmed.
The largest buyer was Broadwood Capital, adding an estimated $4.03M. The largest seller was Family Management, cutting an estimated $119K.
- 75 institutional investors held Asterias Biotherapeutics Inc. Series A (AST) as of Q4 2017, up from 62 in Q3 2017.
- Funds reported $25.5M of Asterias Biotherapeutics Inc. Series A stock for Q4 2017, down 20% quarter-over-quarter.
- 19 funds opened new Asterias Biotherapeutics Inc. Series A positions in Q4 2017 and 6 closed out, a net change of +13 holders.
- The largest Asterias Biotherapeutics Inc. Series A buyer in Q4 2017 was Broadwood Capital, an estimated $4.03M added.
- The largest Asterias Biotherapeutics Inc. Series A seller in Q4 2017 was Family Management, an estimated $119K sold.
Based on aggregated 13F filings for Q4 2017.